JP2010511382A5 - - Google Patents

Download PDF

Info

Publication number
JP2010511382A5
JP2010511382A5 JP2009539218A JP2009539218A JP2010511382A5 JP 2010511382 A5 JP2010511382 A5 JP 2010511382A5 JP 2009539218 A JP2009539218 A JP 2009539218A JP 2009539218 A JP2009539218 A JP 2009539218A JP 2010511382 A5 JP2010511382 A5 JP 2010511382A5
Authority
JP
Japan
Prior art keywords
seq
ack1
amino acid
nucleic acid
kinase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009539218A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010511382A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/SG2007/000412 external-priority patent/WO2008066498A1/en
Publication of JP2010511382A publication Critical patent/JP2010511382A/ja
Publication of JP2010511382A5 publication Critical patent/JP2010511382A5/ja
Pending legal-status Critical Current

Links

JP2009539218A 2006-12-01 2007-12-03 癌関連タンパク質キナーゼ Pending JP2010511382A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86817306P 2006-12-01 2006-12-01
PCT/SG2007/000412 WO2008066498A1 (en) 2006-12-01 2007-12-03 Cancer-related protein kinases

Publications (2)

Publication Number Publication Date
JP2010511382A JP2010511382A (ja) 2010-04-15
JP2010511382A5 true JP2010511382A5 (enExample) 2011-01-27

Family

ID=39468190

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009539218A Pending JP2010511382A (ja) 2006-12-01 2007-12-03 癌関連タンパク質キナーゼ

Country Status (5)

Country Link
US (1) US20110008347A1 (enExample)
EP (1) EP2094850B1 (enExample)
JP (1) JP2010511382A (enExample)
SG (1) SG177225A1 (enExample)
WO (1) WO2008066498A1 (enExample)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120208824A1 (en) 2006-01-20 2012-08-16 Cell Signaling Technology, Inc. ROS Kinase in Lung Cancer
MX2009007216A (es) * 2007-01-11 2009-07-10 Genentech Inc Variaciones geneticas asociadas con tumores.
SI2199390T1 (sl) 2007-08-30 2017-02-28 Daiichi Sankyo Company, Limited Proti-epha2 protitelo
EP2235055A2 (en) * 2007-12-24 2010-10-06 Oxford Biotherapeutics Ltd. Ephrin type-a receptor 10 protein
BRPI0905948A2 (pt) * 2008-02-05 2015-06-30 Urifer Ltd Sequência de nucleotídeo, sequência de nucleotídeo de interfêrencia curta, composição farmacêutica, método para identificar um estado canceroso em uma célula, kit para identificar um estado canceroso em uma célula, método de tratamento do câncer e polipeptídeo
MX2010013333A (es) 2008-06-04 2011-04-05 Amgen Inc Mutantes fgf21 y usos de los mismos.
EP2165710A1 (en) * 2008-09-19 2010-03-24 Institut Curie Tyrosine kinase receptor Tyro3 as a therapeutic target in the treatment of a bladder tumor
EP2169071A1 (en) * 2008-09-29 2010-03-31 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Rodent cancer model for human FGFR4 Arg388 polymorphism
EA032727B1 (ru) 2008-10-10 2019-07-31 Амген Инк. Мутантный резистентный к протеолизу полипептид fgf21 и его применение
CA2741087A1 (en) * 2008-10-21 2010-04-29 Bayer Healthcare Llc Identification of signature genes associated with hepatocellular carcinoma
EP2358375B1 (en) 2008-11-12 2013-07-24 Tengion, Inc. Isolated renal cells and uses thereof
JP5979877B2 (ja) * 2009-02-12 2016-08-31 セル・シグナリング・テクノロジー・インコーポレイテツド ヒト癌における変異ｒｏｓ発現
US20120052069A1 (en) 2009-05-05 2012-03-01 Amgen Inc Fgf21 mutants and uses thereof
TWI560197B (en) 2009-05-05 2016-12-01 Amgen Inc Fgf21 mutants and uses thereof
EP2336171A1 (en) * 2009-12-11 2011-06-22 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Novel targets for the treatment of proliferative diseases
JP2013523184A (ja) 2010-04-15 2013-06-17 アムジエン・インコーポレーテツド ヒトＦＧＦ受容体およびβ−ＫＬＯＴＨＯ結合性タンパク質
EP2380909A1 (en) * 2010-04-26 2011-10-26 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. PTK-7 protein involved in breast cancer
TWI690320B (zh) 2010-05-12 2020-04-11 開曼群島商英瑞金公司 生物活性腎細胞
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
WO2012068073A2 (en) 2010-11-15 2012-05-24 University Of Florida Research Foundation, Inc. Therapeutic and diagnostic applications targeting tnk-1
CA2818992C (en) 2010-12-01 2021-05-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric rabbit/human ror1 antibodies
AU2012346540C1 (en) * 2011-11-30 2019-07-04 Genentech, Inc. ErbB3 mutations in cancer
DK3122375T3 (da) 2014-03-28 2021-05-25 Univ Washington Through Its Center For Commercialization Vacciner mod bryst- og ovariecancer
US11946934B2 (en) 2014-09-03 2024-04-02 Wellmarker Bio Co., Ltd. Biomarker for predicting the sensitivity to a protein kinase inhibitor and a use thereof
US9994914B2 (en) 2014-10-09 2018-06-12 Roche Molecular Systems, Inc. Mutation in the epidermal growth factor receptor kinase domain
AU2016270321B2 (en) * 2015-05-29 2020-09-10 Ignyta, Inc. Compositions and methods for treating patients with RTK mutant cells
EP3365335B1 (en) 2015-10-23 2024-02-14 Array Biopharma, Inc. 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2h)-one compounds as inhibitors of fgfr tyrosine kinases
AU2016345681A1 (en) 2015-10-30 2018-05-10 Nbe-Therapeutics Ag Anti-ROR1 antibodies
EP3405496B1 (en) 2016-01-20 2023-10-25 University of Florida Research Foundation, Incorporated Ror1 antibody compositions and related methods
US11123372B2 (en) 2016-07-29 2021-09-21 Prokidney Bioactive renal cells for the treatment of chronic kidney disease
CN106480205A (zh) * 2016-11-11 2017-03-08 北京吉因加科技有限公司 用于同时检测多种突变类型的序列组合和探针
EP3654952A1 (en) 2017-07-19 2020-05-27 Ignyta, Inc. Pharmaceutical compositions comprising entrectinib
KR20230008269A (ko) 2017-08-07 2023-01-13 엔비이-테라퓨틱스 아게 생체 내 내성이 높은 항체 약물 결합체
JP7311498B2 (ja) 2017-10-17 2023-07-19 イグナイタ インコーポレイテッド 薬学的組成物および剤形
WO2019107671A1 (ko) * 2017-11-29 2019-06-06 서울대학교 산학협력단 항-ros1 항체 및 그의 용도
WO2019133752A1 (en) * 2017-12-28 2019-07-04 Development Center For Biotechnology A method for predicting drug efficacy
CN113474337A (zh) 2018-12-19 2021-10-01 奥瑞生物药品公司 作为fgfr抑制剂用于治疗癌症的7-((3，5-二甲氧基苯基)氨基)喹喔啉衍生物
EP3898626A1 (en) 2018-12-19 2021-10-27 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases
CN113557301B (zh) * 2019-03-04 2025-03-07 公益财团法人东京都医学综合研究所 编码Trk片段的核酸构建体及其利用
CN110031626A (zh) * 2019-04-02 2019-07-19 浙江理工大学 一种用于胃肠道间质肿瘤迁移的标志物ack1及其应用
WO2021138391A1 (en) 2019-12-30 2021-07-08 Tyra Biosciences, Inc. Indazole compounds
US20230115945A1 (en) 2019-12-30 2023-04-13 Tyra Biosciences, Inc. Aminopyrimidine compounds
CR20230325A (es) 2020-12-30 2023-12-11 Tyra Biosciences Inc Compuestos de indazol como inhibidores de cinasas
US20240190849A1 (en) 2021-02-26 2024-06-13 Tyra Biosciences, Inc. Aminopyrimidine compounds and methods of their use
CA3259217A1 (en) 2022-06-29 2024-01-04 Tyra Biosciences, Inc. Indazole compounds
CA3260633A1 (en) 2022-06-29 2024-01-04 Tyra Biosciences, Inc. POLYMORPHIC COMPOUNDS AND THEIR USES
WO2024138112A1 (en) 2022-12-22 2024-06-27 Tyra Biosciences, Inc. Indazole compounds
WO2025129014A1 (en) 2023-12-15 2025-06-19 Tyra Biosciences, Inc. Indazole compounds for the treatment of cancer
WO2025222097A1 (en) 2024-04-19 2025-10-23 Tyra Biosciences, Inc. Indazole-based protac degraders and their anticancer activity
WO2025236094A1 (en) * 2024-05-14 2025-11-20 Narendran Arumugavadivel Identification, design and validation of public neoantigens for the treatment of down syndrome-associated leukemia
WO2026035809A1 (en) 2024-08-06 2026-02-12 Tyra Biosciences, Inc. Indazole compounds for the treatment of cancer

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4343940A (en) * 1979-02-13 1982-08-10 Mead Johnson & Company Anti-tumor quinazoline compounds
EP0031237B1 (en) * 1979-12-19 1984-10-17 National Research Development Corporation Quinazoline derivatives, processes for their preparation, compositions containing them and their use as anti-cancer agents
US4376110A (en) * 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
DE3611194A1 (de) * 1986-04-04 1987-10-08 Bayer Ag Cancerostatisches mittel
US5217999A (en) * 1987-12-24 1993-06-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Styryl compounds which inhibit EGF receptor protein tyrosine kinase
DE3920029C2 (de) * 1988-06-30 1999-05-20 Clariant Finance Bvi Ltd Farbstoffe zum Färben von Kunststoffen
US5302606A (en) * 1990-04-16 1994-04-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase
US5330992A (en) * 1992-10-23 1994-07-19 Sterling Winthrop Inc. 1-cyclopropyl-4-pyridyl-quinolinones
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
SE517975C2 (sv) 2000-05-30 2002-08-13 Power Ab C Fackverkskonstruktion av balkar sammansatta till ett tredimensionellt ramverk samt användning av en sådan fackverkskonstruktion
EP1399584A2 (en) * 2000-10-11 2004-03-24 Avalon Pharmaceuticals Cancer-linked genes as targets for chemotherapy
US20050191618A1 (en) * 2001-05-18 2005-09-01 Sirna Therapeutics, Inc. RNA interference mediated inhibition of human immunodeficiency virus (HIV) gene expression using short interfering nucleic acid (siNA)
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
US20060194265A1 (en) * 2001-10-23 2006-08-31 Morris David W Novel therapeutic targets in cancer
AU2003225535A1 (en) * 2002-01-31 2003-09-02 Millennium Pharmaceuticals, Inc. Methods and compositions for treating cancer
JP2006174701A (ja) * 2003-02-24 2006-07-06 Research Association For Biotechnology 新規タンパク質およびそれをコードするｄｎａ
JP2005198640A (ja) * 2003-11-25 2005-07-28 Biomarker Science:Kk 遺伝子発現方法

Similar Documents

Publication Publication Date Title
JP6076581B2 (ja) Ｔｉａｂｓを検出するための組成物及び方法
JP2019176878A (ja) Ｄｎａ−蛋白質複合体の組成物
KR20080114689A (ko) 증가된 ｂｃｌ-2에 의한 암의 발견
JP2018171062A (ja) ダイナミックｂｈ３プロファイリング
JP2008249727A5 (enExample)
JP2011506941A5 (enExample)
WO2015184443A1 (en) Activating ntrk1 gene fusions predictive of kinase inhibitor therapy
EP2965090A1 (en) Methods and compositions for the diagnosis of alzheimer's disease
JP2008509673A5 (enExample)
US20230417742A1 (en) Improved assays to detect nucleosome modifications using antibody-targeted enzyme digestion
JP2011517937A5 (enExample)
JP2021510306A (ja) ゲノム遺伝子座におけるヌクレオソーム修飾及び変異の定量化のための方法並びにその臨床応用
JP2009539370A5 (enExample)
JP2022520616A (ja) クロマチン会合タンパク質の定量的マッピング
CN111480079A (zh) 疾病蛋白质组蛋白质阵列及其应用
CA2687937C (en) Novel gpiiia gene
US20140065610A1 (en) Method for predicting clinical benefit in the treatment of neurodevelopmental, neurological or neuropsychiatric disorders
KR102232200B1 (ko) 알츠하이머치매 진단 바이오마커
EP1880024A2 (en) Polymorphic ghsr nucleic acids and uses thereof
KR102131860B1 (ko) 아르기닌이 메틸화된 ggt1에 특이적으로 결합하는 대장암 진단용 바이오마커 조성물
KR20120094173A (ko) 유방암 줄기세포 특이적 마커인 ｃｄ４４ 단백질 표적용 펩타이드 및 이의 이용
US10745439B2 (en) Kinase substrates and methods of use thereof
US20140094384A1 (en) Stromal antigen 2 (stag2) compositions and methods
US8765919B2 (en) TOX3 as a biomarker for breast cancer
KR102128251B1 (ko) 아르기닌이 메틸화된 drd2에 특이적으로 결합하는 대장암 진단용 바이오마커 조성물